Potentiation of ICI182,780 (Fulvestrant)-induced Estrogen Receptor-α Degradation by the Estrogen Receptor-related Receptor-α Inverse Agonist XCT790* - Journal of Biological Chemistry
Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate Immobilization and Degradation of Estrogen Receptor-α* - Journal of Biological Chemistry
A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling.,Cell Chemical Biology - X-MOL
Impact of Apparent Antagonism of Estrogen Receptor β by Fulvestrant on Anticancer Activity of 2-Methoxyestradiol | Anticancer Research
IJMS | Free Full-Text | Estrogen Receptors-Mediated Apoptosis in Hormone-Dependent Cancers | HTML
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action | British Journal of Cancer
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer | Journal of Medicinal Chemistry
Estrogen signaling: An emanating therapeutic target for breast cancer treatment - ScienceDirect
Estrogen receptor-α signaling in post-natal mammary development and breast cancers | SpringerLink
Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF‑κB pathway (Review)
Transrepression of estrogen receptor and NFκB. (a) NFκB can inhibit... | Download Scientific Diagram
Estrogen receptor signaling as a target for novel breast cancer therapeutics - ScienceDirect
Cross-talk between nuclear receptors and nuclear factor κB | Oncogene
Molecular mechanism of estrogen–estrogen receptor signaling - Yaşar - 2017 - Reproductive Medicine and Biology - Wiley Online Library
The NF-KB pathway and endocrine therapy resistance in breast cancer in: Endocrine-Related Cancer Volume 26 Issue 6 (2019)
Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy. - Abstract - Europe PMC
Crossroads of Estrogen Receptor and NF-κB Signaling | Science's STKE
Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways in: Journal of Molecular Endocrinology Volume 41 Issue 5 (2008)
Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer | Breast Cancer Research | Full Text